BeOne Medicines (ONC) Short-Term Debt repayments (2020 - 2025)

BeOne Medicines (ONC) has 6 years of Short-Term Debt repayments data on file, last reported at $769.0 million in Q4 2025.

• Quarterly Short-Term Debt repayments rose 40.66% year-over-year to $769.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $871.9 million (down 0.6% YoY) and the FY2025 annual result came in at $1.0 billion, up 48.36% from the prior year.
• Short-Term Debt repayments climbed to $769.0 million in Q4 2025 per ONC's latest filing, from $102.9 million in the prior quarter.
• Across five years, Short-Term Debt repayments topped out at $769.0 million in Q4 2025 and bottomed at $16.0 million in Q2 2021.
• The 5-year median for Short-Term Debt repayments is $97.9 million (2023), against an average of $170.1 million.
• The widest annual swing landed in 2021, when Short-Term Debt repayments soared 1575.76%; it then sank 60.78% in 2023.
• Tracing ONC's Short-Term Debt repayments over 5 years: stood at $205.2 million in 2021, then soared by 32.37% to $271.7 million in 2022, then sank by 44.78% to $150.0 million in 2023, then soared by 264.48% to $546.7 million in 2024, then jumped by 40.66% to $769.0 million in 2025.
• Per Business Quant, the three latest ONC Short-Term Debt repayments figures stand at $769.0 million (Q4 2025), $102.9 million (Q2 2025), and $172.9 million (Q1 2025).

Peer Comparison